Baseline Characteristics of Patients With PCR-Confirmed P. falciparum Infection
| Characteristic . | PCR-Confirmed P. falciparum Infection . | |
|---|---|---|
| . | Dihydroartemisinin-Piperaquine Group . | Artemether-Lumefantrine Group . |
| No. of evaluable patients | 59 | 55 |
| Infecting species at enrollment,a No. (%) | ||
| P. falciparum | 36 (61.0) | 39 (70.9) |
| P. falciparum and P. vivax | 9 (15.3) | 5 (9.1) |
| P. falciparum and P. malariae | 2 (3.4) | 0 (0) |
| P. falciparum and P. knowlesi | 8 (13.6) | 10 (18.2) |
| P. falciparum, P. vivax, P. malariae | 1 (1.7) | 0 (0) |
| P. falciparum, P. vivax, P. knowlesi | 1 (1.7) | 1 (1.8) |
| P. falciparum, P. malariae, P. knowlesi | 2 (3.4) | 0 (0) |
| Median P. falciparum enrollment density (IQR), µL-1 | 320 (272–1160) | 400 (272–1520) |
| Female sex, No. (%) | 35 (59.3) | 25 (45.5) |
| Age | ||
| Median (25%–75% range), y | 11.8 (7–21) | 22 (8–39) |
| <5 y, No. (%) | 10 (16.9) | 5 (9.1) |
| 5–14 y, No. (%) | 30 (50.9) | 20 (36.4) |
| ≥15 y, No. (%) | 19 (32.2) | 30 (54.6) |
| Temperature ≥37.5°C, No. (%) | 9 (15.3) | 8 (14.6) |
| Mean hemoglobin at enrollment (SD), g/dL | 11.7 (1.9) | 11.9 (1.7) |
| Mean hemoglobin at day 28 (SD), g/dL | 11.8 (1.5) | 11.7 (1.9) |
| No. of anemic patients (Hb <10.0 g/dL) (%) | 8 (13.6) | 4 (7.3) |
| Characteristic . | PCR-Confirmed P. falciparum Infection . | |
|---|---|---|
| . | Dihydroartemisinin-Piperaquine Group . | Artemether-Lumefantrine Group . |
| No. of evaluable patients | 59 | 55 |
| Infecting species at enrollment,a No. (%) | ||
| P. falciparum | 36 (61.0) | 39 (70.9) |
| P. falciparum and P. vivax | 9 (15.3) | 5 (9.1) |
| P. falciparum and P. malariae | 2 (3.4) | 0 (0) |
| P. falciparum and P. knowlesi | 8 (13.6) | 10 (18.2) |
| P. falciparum, P. vivax, P. malariae | 1 (1.7) | 0 (0) |
| P. falciparum, P. vivax, P. knowlesi | 1 (1.7) | 1 (1.8) |
| P. falciparum, P. malariae, P. knowlesi | 2 (3.4) | 0 (0) |
| Median P. falciparum enrollment density (IQR), µL-1 | 320 (272–1160) | 400 (272–1520) |
| Female sex, No. (%) | 35 (59.3) | 25 (45.5) |
| Age | ||
| Median (25%–75% range), y | 11.8 (7–21) | 22 (8–39) |
| <5 y, No. (%) | 10 (16.9) | 5 (9.1) |
| 5–14 y, No. (%) | 30 (50.9) | 20 (36.4) |
| ≥15 y, No. (%) | 19 (32.2) | 30 (54.6) |
| Temperature ≥37.5°C, No. (%) | 9 (15.3) | 8 (14.6) |
| Mean hemoglobin at enrollment (SD), g/dL | 11.7 (1.9) | 11.9 (1.7) |
| Mean hemoglobin at day 28 (SD), g/dL | 11.8 (1.5) | 11.7 (1.9) |
| No. of anemic patients (Hb <10.0 g/dL) (%) | 8 (13.6) | 4 (7.3) |
Abbreviations: IQR, interquartile range; PCR, polymerase chain reaction.
aIdentification and measurement by microscopy.
Baseline Characteristics of Patients With PCR-Confirmed P. falciparum Infection
| Characteristic . | PCR-Confirmed P. falciparum Infection . | |
|---|---|---|
| . | Dihydroartemisinin-Piperaquine Group . | Artemether-Lumefantrine Group . |
| No. of evaluable patients | 59 | 55 |
| Infecting species at enrollment,a No. (%) | ||
| P. falciparum | 36 (61.0) | 39 (70.9) |
| P. falciparum and P. vivax | 9 (15.3) | 5 (9.1) |
| P. falciparum and P. malariae | 2 (3.4) | 0 (0) |
| P. falciparum and P. knowlesi | 8 (13.6) | 10 (18.2) |
| P. falciparum, P. vivax, P. malariae | 1 (1.7) | 0 (0) |
| P. falciparum, P. vivax, P. knowlesi | 1 (1.7) | 1 (1.8) |
| P. falciparum, P. malariae, P. knowlesi | 2 (3.4) | 0 (0) |
| Median P. falciparum enrollment density (IQR), µL-1 | 320 (272–1160) | 400 (272–1520) |
| Female sex, No. (%) | 35 (59.3) | 25 (45.5) |
| Age | ||
| Median (25%–75% range), y | 11.8 (7–21) | 22 (8–39) |
| <5 y, No. (%) | 10 (16.9) | 5 (9.1) |
| 5–14 y, No. (%) | 30 (50.9) | 20 (36.4) |
| ≥15 y, No. (%) | 19 (32.2) | 30 (54.6) |
| Temperature ≥37.5°C, No. (%) | 9 (15.3) | 8 (14.6) |
| Mean hemoglobin at enrollment (SD), g/dL | 11.7 (1.9) | 11.9 (1.7) |
| Mean hemoglobin at day 28 (SD), g/dL | 11.8 (1.5) | 11.7 (1.9) |
| No. of anemic patients (Hb <10.0 g/dL) (%) | 8 (13.6) | 4 (7.3) |
| Characteristic . | PCR-Confirmed P. falciparum Infection . | |
|---|---|---|
| . | Dihydroartemisinin-Piperaquine Group . | Artemether-Lumefantrine Group . |
| No. of evaluable patients | 59 | 55 |
| Infecting species at enrollment,a No. (%) | ||
| P. falciparum | 36 (61.0) | 39 (70.9) |
| P. falciparum and P. vivax | 9 (15.3) | 5 (9.1) |
| P. falciparum and P. malariae | 2 (3.4) | 0 (0) |
| P. falciparum and P. knowlesi | 8 (13.6) | 10 (18.2) |
| P. falciparum, P. vivax, P. malariae | 1 (1.7) | 0 (0) |
| P. falciparum, P. vivax, P. knowlesi | 1 (1.7) | 1 (1.8) |
| P. falciparum, P. malariae, P. knowlesi | 2 (3.4) | 0 (0) |
| Median P. falciparum enrollment density (IQR), µL-1 | 320 (272–1160) | 400 (272–1520) |
| Female sex, No. (%) | 35 (59.3) | 25 (45.5) |
| Age | ||
| Median (25%–75% range), y | 11.8 (7–21) | 22 (8–39) |
| <5 y, No. (%) | 10 (16.9) | 5 (9.1) |
| 5–14 y, No. (%) | 30 (50.9) | 20 (36.4) |
| ≥15 y, No. (%) | 19 (32.2) | 30 (54.6) |
| Temperature ≥37.5°C, No. (%) | 9 (15.3) | 8 (14.6) |
| Mean hemoglobin at enrollment (SD), g/dL | 11.7 (1.9) | 11.9 (1.7) |
| Mean hemoglobin at day 28 (SD), g/dL | 11.8 (1.5) | 11.7 (1.9) |
| No. of anemic patients (Hb <10.0 g/dL) (%) | 8 (13.6) | 4 (7.3) |
Abbreviations: IQR, interquartile range; PCR, polymerase chain reaction.
aIdentification and measurement by microscopy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
